MARKET

BAX

BAX

Baxter Intl
NYSE

Real-time Quotes | Nasdaq Last Sale

78.28
+0.22
+0.28%
After Hours: 78.28 0 0.00% 16:00 03/08 EST
OPEN
78.21
PREV CLOSE
78.06
HIGH
79.30
LOW
77.65
VOLUME
1.55M
TURNOVER
--
52 WEEK HIGH
95.19
52 WEEK LOW
69.10
MARKET CAP
39.53B
P/E (TTM)
36.72
1D
5D
1M
3M
1Y
5Y
Baxter International Inc. stock rises Monday, outperforms market
Shares of Baxter International Inc. inched 0.28% higher to $78.28 Monday, on what proved to be an all-around mixed trading session for the stock market, with...
marketwatch.com · 4h ago
Globa Patient Monitoring Devices Market Research Report 2020 Market Size, Share, Value, and Competitive Landscape forecast year
Mar 08, 2021 (Heraldkeepers) -- Patient Monitoring Devices Market: Market Segments: By Type (Hemodynamic Monitoring, Neuromonitoring, Cardiac Monitoring,...
Heraldkeepers · 7h ago
Moderna ropes in Baxter for fill/finish manufacturing of COVID-19 vaccine
Baxter International ([[BAX]] +0.9%) has agreed to provide fill/finish sterile manufacturing services and supply packaging for ~60-90M doses of the COVID-19 vaccine developed Moderna ([[MRNA]] -3.5%).The production planned for 2021 will take
Seekingalpha · 8h ago
Burn Care Products & Accessories Market Share, Development by Companies Outlook, Growth Prospects and Key Opportunities by 2030
Mar 08, 2021 (Heraldkeepers) -- The global Burn Care Products & Accessories market report provides geographic analysis covering regions, such as North...
Heraldkeepers · 9h ago
Cancer Immunomodulator Market Size, Share & Trends Analysis Report With Growth Forecast 2020-2027
Mar 08, 2021 (Heraldkeepers) -- Market Research Engine has published a new report titled as "Cancer Immunomodulator Market Size By Product (Method of Use:...
Heraldkeepers · 9h ago
Blood Testing Market Share, Size, Trends, Industry Analysis to 2027 by Disease Type; By Technology; By Specialty; By End-Use; By Regions
Mar 08, 2021 (Heraldkeepers) -- The Blood Testing Market is expected to exceed more than US$ 60.8 Billion by 2024 at a CAGR of 2.5% in the given forecast...
Heraldkeepers · 9h ago
Moderna Signs Vial-Filling Deal With Baxter to Bolster Supply
Moderna Inc. added a second partner in the U.S. to help fill vaccine vials, inking a deal with Baxter International Inc. to help the company produce 60 million to 90 million Covid vaccine doses in 2021.
Bloomberg · 10h ago
Baxter To Offer Fill/Finish Services To Moderna's COVID-19 Vaccine In US
Benzinga · 11h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BAX. Analyze the recent business situations of Baxter Intl through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BAX stock price target is 92.18 with a high estimate of 105.00 and a low estimate of 80.00.
EPS
Institutional Holdings
Institutions: 1.60K
Institutional Holdings: 453.37M
% Owned: 89.76%
Shares Outstanding: 505.10M
TypeInstitutionsShares
Increased
323
37.07M
New
194
-2.70M
Decreased
399
37.26M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.72%
Healthcare Equipment & Supplies
-1.34%
Key Executives
Chairman/President/Chief Executive Officer/Director
Jose Almeida
Chief Financial Officer/Executive Vice President
James Saccaro
Senior Vice President/Chief Accounting Officer/Controller
Brian Stevens
Senior Vice President/General Counsel
Sean Martin
Senior Vice President/Director of Human Resources
Jeanne Mason
Senior Vice President
Giuseppe Accogli
Senior Vice President
Cristiano Franzi
Senior Vice President
Andrew Frye
Senior Vice President
Jacqueline Kunzler
Lead Director/Independent Director
Albert Stroucken
Director
David Wilkes
Independent Director
Thomas Chen
Independent Director
John Forsyth
Independent Director
James Gavin
Independent Director
Peter Hellman
Independent Director
Michael Mahoney
Independent Director
Patricia Morrison
Independent Director
Stephen Oesterle
Independent Director
Cathy Smith
Independent Director
Thomas Stallkamp
Independent Director
Amy Wendell
Declaration Date
Dividend Per Share
Ex-Div Date
02/16/2021
Dividend USD 0.245
02/25/2021
11/16/2020
Dividend USD 0.245
12/03/2020
07/14/2020
Dividend USD 0.245
08/28/2020
05/05/2020
Dividend USD 0.245
06/04/2020
02/18/2020
Dividend USD 0.22
02/27/2020
11/19/2019
Dividend USD 0.22
12/05/2019
07/16/2019
Dividend USD 0.22
08/29/2019
05/07/2019
Dividend USD 0.22
06/06/2019
02/19/2019
Dividend USD 0.19
02/28/2019
11/13/2018
Dividend USD 0.19
11/30/2018
07/17/2018
Dividend USD 0.19
08/30/2018
05/08/2018
Dividend USD 0.19
05/31/2018
02/20/2018
Dividend USD 0.16
03/01/2018
11/14/2017
Dividend USD 0.16
11/30/2017
07/18/2017
Dividend USD 0.16
08/30/2017
05/02/2017
Dividend USD 0.16
05/31/2017
02/21/2017
Dividend USD 0.13
03/01/2017
11/08/2016
Dividend USD 0.13
11/30/2016
07/19/2016
Dividend USD 0.13
08/31/2016
05/03/2016
Dividend USD 0.13
06/01/2016
02/16/2016
Dividend USD 0.115
03/02/2016
11/10/2015
Dividend USD 0.115
12/02/2015
07/30/2015
Dividend USD 0.115
09/02/2015
05/05/2015
Dividend USD 0.52
05/28/2015
02/17/2015
Dividend USD 0.52
03/09/2015
11/11/2014
Dividend USD 0.52
12/03/2014
07/22/2014
Dividend USD 0.52
09/03/2014
05/05/2014
Dividend USD 0.52
06/04/2014
02/18/2014
Dividend USD 0.49
03/05/2014
11/12/2013
Dividend USD 0.49
12/04/2013
07/24/2013
Dividend USD 0.49
09/04/2013
About BAX
Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.

Webull offers kinds of Baxter International Inc stock information, including NYSE:BAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BAX stock methods without spending real money on the virtual paper trading platform.